REG - Feedback PLC - Director/PDMR Shareholding

FeedbackAnnouncement

02/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241202:nRSB2801Oa&default-theme=true

RNS Number : 2801O  Feedback PLC  02 December 2024

 

Feedback Plc

 

Director/PDMR shareholding

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, announces that on 29 November 2024 the Company was
notified of the following Directors' dealing(s) in the Company's ordinary
shares of 1 penny each ("Ordinary Shares"):

 

Rory Shaw, Non-Executive Chairman, has purchased 49,261 Ordinary Shares at a
price of 20.3 pence per Ordinary Share.

 

Philipp Prince, Non-Executive Director, has purchased 35,469 Ordinary Shares
at a price of 20.2 pence per Ordinary Share. He has also sold 20,232 Ordinary
Shares at a price of 19.6 pence per Ordinary Share. This was done to move the
holding from a SIPP to an ISA.

 

Details of the Ordinary Shares held are detailed in the table below:

 

 Director/ PDMR   Position                Existing interest in Ordinary Shares  Ordinary Shares purchased  Ordinary Shares sold  Total beneficial interest in Ordinary Shares  Total interest in Company's issued share capital
 Rory Shaw        Non-Executive Chairman  103,573                               49,261                     -                     152,834                                       0.35%
                  Non-Executive Director  24,763                                35,469                     20,232                40,000                                        0.09%

 Philipp Prince

 

 

The notification set out below, provides further details of such dealings:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Names                                                        Rory Shaw

                                                                   Philipp Prince

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

                                                                   Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Feedback plc

 b)   LEI                                                          213800UGOF2GT2U2RV90

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 penny each in Feedback plc

      Identification code                                          GB00BJN59X09

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

                                                                   Purchase of Ordinary Shares / Sale of Ordinary Shares
 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     20.3p             49,261
                                                                                     20.2p / 19.6p     35,469 / 20,232

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction                                      28 November 2024

                                                                   29 November 2024
 f)   Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

 

 

Enquiries:

 

 Feedback plc                                 +44 (0) 20 3997 7634

 Tom Oakley, CEO                              IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Liberum Limited (NOMAD and Broker)   +44 (0)20 7886 2500

 Emma Earl/ Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                             Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                              (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                         07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for
patients. We design products that enhance clinician access to patient data and
to their colleagues. Our unique approach centres around individual patient
episodes, into which we pull relevant clinical data from hospital systems and
around which we build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available to
clinicians in multiple settings, in a format that enables them to meaningfully
interact with it, providing flexibility to clinicians and free movement of
patients between provider settings - clinicians can practice from anywhere and
patients can attend any care provider for treatment, with greater connectivity
across organisations.

 

Our products Bleepa® and CareLocker® work together to deliver unparalleled
value to our customers. Bleepa® is our application layer and sits on top of
CareLocker® as our data layer. Bleepa® is a clinician facing platform that
displays clinical results from a patient's CareLocker® at a certified and
regulated quality, that is suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure, auditable chat
interface that links back to the patient medical record. The CareLocker® data
storage model is built around the patient. Our vision is one where relevant
clinical data is always available to the patient as well as to any care
setting that they may attend - a federated data architecture with the patient
as the tenant.

 

The Company has a number of growth opportunities domestically and
internationally across a range of markets including the NHS and private
healthcare providers and its highly scalable Software as a Service
("SaaS")-based model is expected to provide increasing levels of revenue
visibility as the Company grows its customer base.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPGGCPUPCGQG